Analysts who follow Lineage Cell Therapeutics Inc (LCTX) on average expect it to rise 466.60% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy.
That average rating earns the stock an Analyst Ranking of 68, which means it ranks higher than 68 of stocks, based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
Investors Observer averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Lineage Cell Therapeutics Inc Stock Today?
Lineage Cell Therapeutics Inc (LCTX) stock is up 2.04% while the S&P 500 is lower by -1.56% as of 9:42 AM on Monday, Sep 21. LCTX is higher by $0.02 from the previous closing price of $0.98 on volume of 2,136 shares. Over the past year the S&P 500 is up 9.22% while LCTX is lower by -2.91%. LCTX lost -$0.24 per share the over the last 12 months.
Click Here to get the full report on Lineage Cell Therapeutics Inc (LCTX) Stock.
